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DAbstract Corynebacterium pseudotuberculosis (C. pseudotuberculosis) is a causative organism of
caseous lymphadenitis (CLA) in sheep and acute disease in buffaloes known as oedematous skin
disease (OSD). Human affected with the disease show liver abscess and abscess in the internal
lymph nodes. The vaccination against CLA up till now occurs by using formalin inactivated whole
cells of biovar 1 (sheep strain). Combined vaccine composed of formalin inactivated whole cells of
sheep strain and recombinant phospholipase D (rPLD) and another vaccine composed of formalin
inactivated whole cells (buffalo origin) and rPLD were prepared in Biotechnology center for ser-
vices and Researches laboratory at Cairo university and applied for protection against CLA. Both
vaccines induced complete protection (100%) against challenge with virulent biovar 1 or biovar 2.
Also vaccination against OSD was performed by two types of vaccines. Vaccine-1 was composed of
formalin inactivated whole cell biovar 1 combined with rPLD and the second vaccine was composed
of formalin inactivated whole cells of biovar 2 combined with rPLD. No lesions developed in vac-
cinated and non vaccinated buffaloes challenged with C. pseudotuberculosis biovar revealing that
biovar 1 C. pseudotuberculosis is not infective for buffaloes. Buffaloes vaccinated with the secondh 11451,
Vaccination against Corynebacterium pseudotuberculosis 719vaccine and control non vaccinated animals challenged with biovar 2 (buffalo origin) resulted in
development of OSD in all animals. This indicates that OSD results due to production of toxin
(s) other than PLD. Discovering this toxin (s) is of value in formulation of a future vaccine against
OSD.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Corynebacterium pseudotuberculosis is a Gram positive faculta-
tive intracellular organism causing caseous lymphadenitis
(CLA) in sheep and goats. The disease characterized by
chronic suppurative inﬂammation and signiﬁcant economical
losses to the sheep industries worldwide (Paton et al., 2003;
Dorella et al., 2006).
In human, it is of major occupational impact. Human
affected with the disease show liver abscess and abscess in
the internal lymph nodes.
C. pseudotuberculosis causes a characteristic acute disease in
buffaloes known as Oedematus skin disease (OSD). The dis-
ease is endemic in Egypt and is characterized by the develop-
ment of diffused swellings in the skin of the hind quarter,
fore limbs, belly and brisket regions. These lesions usually
affect the lymph nodes which become enlarged and inﬂamed
and ﬁlled with pus. At ﬁrst is ﬁlled with serous ﬂuid then
turned to sac of pus due to contamination with other bacteria
as staphylococci, streptococci, E. coli and Pseudomonas. The
disease is characterized by high morbidity and low mortality
and the badly treated cases died. OSD is a terrible disease
for farmers and veterinarians; it causes severe economical
losses due to the necessary surgical intervention, expensive
medication, reduction in the milk production and lowering
of work activity of the affected animals (Selim, 2001). In
human infections caused by C. pseudotuberculosis most com-
monly occur by the occupational exposure, ingestion of raw
milk from goat and cow’s milk (Peel et al., 1997).
The majority of studies have employed formalin inactivated
toxoid vaccines derived from phospholipase D (PLD) rich C.
pseudotuberculosis culture supernatants and these have con-
ferred varying levels of protective immunity in both sheep and
goats (Narin et al., 1977 andEggleton et al., 2005). In the present
investigation two combined vaccines prepared from formalin
inactivated whole cells of biovar 1 (sheep origin) in each dose,
the second vaccine is composed of inactivated whole cells of bio-
var 2 (buffalo origin) in combination with rPLD. These vaccines
will be used for vaccination of sheep and buffaloes and protec-
tive efﬁcacywas assessed by virulent strains locally isolated from
sheep with CLA or buffaloes with OSD.
2. Materials and methods
2.1. Animals
2.1.1. Sheep
Eight sheep approximately 8–10 months old were tested by
ELISA to exclude the positive reactors. Negative ELISA (free
of CLA) animals were divided into 4 groups. Group 1 vacci-
nated with bacterins (biovar 1) and rPLD and second group
vaccinated with heterologon bacterin (biovar 2) and rPLD.Animals of group 1 in addition to 2 control non vaccinated
animals were challenged with virulent biovar 1 and second vac-
cinated group with 2 control animals were challenged with vir-
ulent biovar 2 (isolated from buffaloes with OSD).
2.1.2. Buffaloes
Eight buffaloes approximately 4–6 months old previously
tested with ELISA for exclusion of positive reactors. Negative
ELISA animals were divided into 4 groups. The ﬁrst group
were vaccinated with vaccine composed of formalin inacti-
vated whole cell of biovar 1 (sheep origin) with rPLD. Vacci-
nated animals and control 2 animals were challenged with
virulent biovar 2 isolate obtained from buffaloes with OSD.
2.2. Formalin whole cell bacterin
Two types of bacterins were prepared. The ﬁrst bacterin was
prepared from C. pseudotuberculosis biovar 1 (sheep origin)
and the second bacterin was prepared from biovar 2 (buffalo
origin). Preparations were performed according to Brogden
et al. (1990) with modiﬁcation. Each dose (2 ml of bacterin
1) contained 20 mg of killed bacteria. In bacterin 2 each dose
(4 ml) contained 100 mg of killed bacteria (biovar 2).
2.3. Vaccine formulations
2.3.1. Vaccine 1
It is composed 20 mg bacterin combined (sheep origin) with
rPLD (50 lg) in volume 1 ml. then combined vaccine was
mixed with 1 ml of oil adjuvant to bacterin a dose of 2 ml.
2.3.2. Vaccine 2
It is composed of bacterin prepared from biovar 2 (buffalo ori-
gin) and proceeded as in vaccine 1.
2.3.3. Vaccine 3
It is composed of bacterin prepared from biovar 1 (sheep iso-
late), but with concentration of 100 mg killed whole cells in a
volume 2 ml. To bacterin 500 lg of rPLD were added in a vol-
ume of 2 ml. To 2 ml suspension of combined bacterin and
rPLD 2 ml of oil adjuvant were added to obtain a ﬁnal volume
of 4 ml.
2.3.4. Vaccine 4
It is composed of bacterin prepared from biovar 2 (buffalo ori-
gin) and proceeded as in vaccine 3.
2.4. Schedule of vaccination
Group 1 and group 2 of sheep were vaccinated with combined
vaccine 1 and 2 respectively by S/C inoculation of 2 ml dose of
720 I.M. Moussa et al.vaccine in middle third of the neck. All the vaccinated animals
were revaccinated after 3 weeks of the ﬁrst vaccination with the
same vaccines.
After 3 weeks of the last vaccination, the vaccinated group
1 animals and the control non vaccinated sheep were chal-
lenged with virulent biovar 1 sheep isolate with 2 ml suspen-
sion contain 2  106 CF distributed intradermally as 1 ml in
both sides of the neck, the second group of sheep were vacci-
nated and challenged by the same manner as with vaccine 1.
The buffaloes of the ﬁrst and second groups of animals
were vaccinated by subcutaneous injection of 2 ml in the neck
and the other 2 ml in the hind limb in one side of the animal
with vaccine 3 and 4, respectively and poster dose was given
after three and six weeks in the same manner. The control ani-
mals were inoculated in the same manner with 4 ml saline adju-
vant mixture.
All vaccinated buffaloes of group, and its control were chal-
lenged with 5 ml of 48 h brain heart broth which contained
5  106 of living cells inoculated intradermally in hairless areas
as axillary and groin folds. The ﬁrst group of animals with its
control non vaccinated was challenged with virulent sheep iso-
late biovar 1 and the second group of buffaloes with its control
non vaccinated was challenged with virulent C. pseudotubercu-
losis isolated from buffaloes (biovar 2).
2.5. Antibodies assayed with ELISA
Blood samples were obtained from sheep before vaccination
and at weekly intervals till the end of experiment (20 weeks).
In case of buffaloes blood samples were collected directly
before vaccination and one week after the ﬁrst dose of vaccina-
tion, then 1 week after the second booster dose, then 3 weeksFigure 1 Antibody titer of the serum samples of sheep collected at
vaccinated with bacterin (sheep) + rPLD; B: Mean OD in sera of sh
challenged with sheep C. pseudotuberculosis D: Control sheep challengand 3 months after challenge. Antibodies were assayed in 96
ELISA plates as previously described by Selim et al. (2016).
2.6. Post mortem and clinical observation
The primary vaccination sites and site of challenge were
inspected at weekly intervals for any signs of local reaction.
All sheep were euthanized and necropsied 20 weeks post pri-
mary vaccination and the external prescapular and prefemoral
lymph nodes were examined in addition to the internal lymph
nodes for abscesses. Swabs were collected from abscesses
developed in control challenged sheep and buffaloes for isola-
tion of C. pseudotuberculosis.
3. Results
3.1. Serological analysis
All vaccinated sheep had an antibody response to rPLD anti-
gen, whereas control sheep remained negative throughout this
serum period. Antibodies appeared in sera of unvaccinated
control animals after exposure to challenge. In vaccinated
groups antibodies increased after second booster dose of vac-
cination, but after exposure to challenge, a slight decrease in
OD of examined animals occurred, but the level of antibodies
persist higher than the cut off value till 20 weeks the time of
slaughtering the animals as shown in Fig. 1.
In case of buffaloes all vaccinated animals showed increase
in antibody levels, while control non vaccinated showed no
titers of antibodies. The highest magnitude of antibodies devel-
oped after booster vaccination but after challenge a slight
decrease was observed and level of antibodies revered totime intervals post immunization. A: Mean OD in sera of sheep
eep vaccinated with bacterin (buffalo) + rPLD; C: Control sheep
ed with buffalo C. pseudotuberculosis.
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and Fig. 2.
3.2. Challenge
Buffaloes vaccinated with bacterin (sheep origin) and rPLD
and the control buffaloes challenged with C. pseudotuberculosis
(sheep origin) developed a swelling at site of inoculation which
spontaneously disappeared, through 15 days. Meanwhile, vac-
cinated buffaloes with bacterin (sheep origin) and rPLD and
challenged with virulent C. pseudotuberculosis of buffalo origin
developed redness, swelling of site of inoculation which
extends to the belly region.
Control non vaccinated and challenged buffaloes with C.
pseudotuberculosis (buffalo origin) developed swelling at the
site of inoculation and extend to the regional lymph node.
On the other hand control non vaccinated buffaloes challengedTable 1 Mean OD of ELISA assay in sera of buffaloes vaccinated
Weeks of
experiment
Buﬀaloes vaccinated with
combined bacterin (sheep)
+ rPLD
Buﬀaloes vaccinated
combined bacterin (b
+ rPLD
After 1st
dose
0.494 0.501
After 2nd
dose
0.678 0.734
3 weeks post
challenge
0.609 0.563
3 months
post
challenge
0.313 0.318
Cut off value: 0.350.
Figure 2 Antibody titer of the serum samples of sheep collected at ti
vaccinated with bacterin (sheep) + rPLD; B: Mean OD in sera of bu
buffaloes challenged with sheep C. pseudotuberculosis D: Control buffwith C. pseudotuberculosis (sheep origin) developed a slight
inﬂammatory medium at site of inoculation which disappears
spontaneously.
All sheep were examined for external and internal
abscesses. Mean number of abscesses for each group was
recorded (Table 2) of group 1 sheep vaccinated with vaccine
(A) (bacterin (biovar1) + rPLD) and challenged with homolo-
gous virulent strain and group 2 vaccinated with vaccine (B)
composed of bacterin (biovar 2) + rPLD). No lesion could
be observed either in external or internal lymph nodes. While
control group non vaccinated animals challenged with virulent
biovar1 developed 12 score lesions. Out of 15 lesions score in
typically discussed sheep will CLA. Hence 12/15 represent
80% susceptibility and 20% naturally protected animals. At
the same time sheep vaccinated with vaccine (B) which was
composed of bacterin (biovar 2) plus rPLD, developed the
same in the form abscess in a percent of 13/15 i.e. 86.6%with combined bacterin + rPLD ‘‘sera dil 1:100”.
with
uﬀalo)
Control buﬀaloes
Challenged with sheep
C. pseudotuberculosis
Challenged with buﬀalo
C. pseudotuberculosis
– –
– –
0.399 0.452
0.211 0.294
me intervals post immunization. A: Mean OD in sera of buffaloes
ffaloes vaccinated with bacterin (buffaloes) + rPLD; C: Control
aloes challenged with buffalo C. pseudotuberculosis.
Table 2 Score of lesions detected during post mortem examination of external and internal lymph nodes of sheep post challenge.
Groups of sheep Mean score lesions Total score of internal lymph
nodes
Total score for each
group
% of
protection
% of
infectionExternal lymph nodes
RPS LPS RPF LPF
Control groups
1-Challenged with biotype 1 3/3 3/3 3/3 0/3 3/3 12/15 20 80
2-Challenged with biotype 2 3/3 3/3 3/3 1/3 3/3 13/15 13.4 86.6
Vaccinated group with
vaccine (A)
0/3 0/3 0/3 0/3 0/3 0/15 100 0
Vaccinated group with
vaccine (B)
0/3 0/3 0/3 0/3 0/3 0/15 100 0
Score: 0 = Normal of slightly enlarged LN (0/3).
1 = Enlarged lymph node (1/3).
2 = Enlarged and congested or hemorrahagic (2/3).
3 = Enlarged lymph node with focal abscess or caseation (3/3).
RPS: Right prescapular lymph node.
LPS: Left prescapular lymph node.
RPF: Right prefemoral lymph node.
LPF: Left prefemoral lymph node.
Internal lymph node one unit (Inguinal, tracheobronchial thoracic, mesenteric, 2 popliteals).
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pseudotuberculosis (nitrate negative) were isolated from group
1 vaccinated animals and C. pseudotuberculosis from abscess
in group 2 vaccinated sheep. These isolates were of nitrate pos-
itive reactors.
3.3. Clinical findings in vaccinated buffaloes
All buffaloes either vaccinated or control non vaccinated
group challenged with C. pseudotuberculosis strain (biotype
1) showed a slight enlargement at site of bacterial inoculation,
which disappeared gradually through 15 days. Another clinical
features were observed in the case of vaccinated buffaloes with
bacterin (biotype 2) + rPLD or control non vaccinated ani-
mals and challenged will ﬁeld strain of C. pseudotuberculosis
isolated from buffaloes diseased with OSD. All animals devel-
oped swellings at site of inoculation which extend to the skin of
belly region associated with redness of skin, in more aged
lesions ulcers were developed at site of inoculation. The sever-
ity of lesions were the same either in vaccinated or non vacci-
nated control group, which indicate the production of
unknown toxin produced by the challenging C. pseudotubercu-
losis strain (biotype 2 buffalo origin) and that could not be
neutralized by antibodies developed against bacterin or PLD
composing the vaccines.4. Discussion
In the present investigation, this is the ﬁrst report describing
immunizations of sheep with bacterins prepared from nitrate
positive C. pseudotuberculosis strain isolated from buffaloes
(biovar 2) and challenged with virulent biovar 2 isolate. No
signiﬁcant difference in protection efﬁcacy of both vaccines
could be observed in challenged sheep either challenged with
virulent biovar 1 or biovar 2. All vaccinated sheep were com-
pletely protected against challenge. At the same time controlnon vaccinated groups either challenged with biovar 1 (sheep
origin) or biovar 2 (buffalo origin) showed the development
of chronic symptoms of CLA characterized by production of
caseous abscess either in external or internal lymph nodes.
These results indicated that C. pseudotuberculosis either of
biovar 1 or biovar 2 induced the same lesion which can be
attributed to the same virulence factor i.e. PLD possessed by
both biovars. Vaccination with a combination of rPLD and
killed whole-cells resulted in complete protection against chal-
lenge (Fontaine et al., 2006). Our ﬁndings are in consistence
with our ﬁnding about complete protection of combined rPLD
and killed whole cells. The results of our study would tend to
support the ﬁndings of pervious authors (Cameron, 1972 and
Cameron and Fuls, 1973).
Interestingly, both PLD and the formalin inactivated whole
cell vaccines prevented dissemination of challenge bacteria
beyond the site of inoculation to essentially equivalent extents.
Cell mediated immunity can be attributed to rPLD which acti-
vate macrophages in vaccinated animals. The role of rPLD in
activation of macrophages has been shown in immune model
(El-Enbaawy et al., 2005).
In the present investigation, ELISAwas used for detection of
antibodies in vaccinated or challenged animals. rPLD was used
for coating well in ELISA plates. ELISA test using rPLD anti-
gen proved to be a highly sensitive test for detection of antibod-
ies in early infection. Test could detect antibodies after one week
of ﬁrst dose of vaccination. On results in usingELISA and rPLD
for diagnosis are consistent with those reported byMenzies et al.
(1994) and Fontaine et al. (2006). Our data derived from testing
serum of naturally CLA positive and truly CLA negative ani-
mals, indicate that PLD-ELISAhas high speciﬁcity and sensitiv-
ity for early diagnosis of CLA and of value in aiding in the
diagnosis and control of CLA infection.
Vaccination with combined rPLD and formalin inactivated
whole cell of C. pseudotuberculosis clearly decreased the preva-
lence and number of abscesses that formed secondary to C.
pseudotuberculosis infection. No abscess developed either exter-
Vaccination against Corynebacterium pseudotuberculosis 723nal or internal lymph nodes in all vaccinated sheep. If compared
with control non vaccinated sheep abscess developed in external
and internal lymph nodes in a percent of 80–87%.
In case of buffaloes vaccinated either with vaccine combined
of formalin whole cell inactivation of biovar 1 (sheep origin) and
its control non vaccinated buffaloes challenged with virulent
biovar 1, no lesion could observed in both group of buffaloes
except the development of localized swelling at site of inocula-
tion, which disappeared spontaneously through 15 days. These
results indicate that sheep (biovar 1) strains are not infections to
buffaloes which they could induce CLA in sheep. In second
group of buffaloes vaccinated with combined whole cells of bio-
var 2 and rPLD and challenged with virulent strain of biovar 2
and its control non vaccinated buffaloes.
All animals developed signs of OSD as swelling at site of
challenge and may extend to the belly region. Ulceration at site
of challenge inoculation occurred in some experiment animals.
These results indicate that development of OSD lesions in both
vaccinated and non vaccinated group of buffaloes resulted
from the production of toxin(s) other than PLD. The produc-
tion of toxins other than PLD could be reported in previous
studies through which buffalo isolates (biovar 2) induced acute
hemorrhagic congestions at site of inoculation while guinea
pigs infected with sheep isolates (biovar 1) resulted in develop-
ment of abscesses at site of inoculation. Our conclusion declar-
ing this toxin(s) produced by C. pseudotuberculosis biovar 2,
other than PLD, will be of value in future development of vac-
cine against OSD.
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